Results 41 to 50 of about 3,710 (152)

Modern view on the place of riociguat in the treatment of pulmonary hypertension [PDF]

Терапевтический архив, 2018
Current research is aimed at studying the fundamental therapeutic targets and discovering new drugs acting on previously set targets. Until recently, the only therapeutic strategy to influence the molecular pathway of nitric oxide (NO) – soluble ...
Z.S. Valieva, I.N. Taran, T.V. Martynyuk, I.Ye. Chazova   +3 more
doaj   +2 more sources

Riociguat for the treatment of pulmonary hypertension.

, 2014
Introduction: Pulmonary arterial hypertension (PAH) is still an incurable disease with high mortality despite recent treatment advances. Chronic thromboembolic pulmonary hypertension (CTEPH) is a specific form of pulmonary hypertension due to ...
Behr, J., Meis, T.
core   +1 more source

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

Arthritis Research & Therapy, 2019
Background To determine the effect of riociguat, an oral, selective soluble guanylate cyclase stimulator, on the net digital ulcer (DU) burden in systemic sclerosis (SSc).
Vivek Nagaraja, Cathie Spino, Erica Bush, Pei-Suen Tsou, Robyn T. Domsic, Robert Lafyatis, Tracy Frech, Jessica K. Gordon, Virginia D. Steen, Dinesh Khanna   +9 more
doaj   +1 more source

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study

International Journal of Cardiology: Heart & Vasculature, 2020
Background: Although balloon pulmonary angioplasty (BPA) improves symptoms and pulmonary hemodynamics in patients with chronic thromboembolic pulmonary hypertension (CTEPH), the effects of riociguat on hemodynamics and exercise capacity in patients after
Tatsuo Aoki, Koichiro Sugimura, Yosuke Terui, Shunsuke Tatebe, Shigefumi Fukui, Masanobu Miura, Saori Yamamoto, Nobuhiro Yaoita, Hideaki Suzuki, Haruka Sato, Katsuya Kozu, Ryo Konno, Satoshi Miyata, Kotaro Nochioka, Kimio Satoh, Hiroaki Shimokawa   +15 more
doaj   +1 more source

Results of long-term riociguat therapy, including a switching strategy from sildenafil, in patients with pulmonary hypertension of various genesis

Евразийский Кардиологический Журнал, 2023
Aim: to study the influence of riociguat on the functional and hemodynamic status, remodeling of the right heart, as well as the safety of therapy in both previously untreated patients with idiopathic pulmonary arterial hypertension (IPAH) and inoperable
S. A. Musashaykhova, Z. S. Valieva, T. V. Martynyuk   +2 more
doaj   +1 more source

Scleroderma‐Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single‐Center Prospective Registry

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective Early diffuse cutaneous systemic sclerosis (dcSSc) is associated with substantial disease‐specific mortality. Scleroderma‐specific autoantibodies (SSc‐Ab) may influence disease course, but their prognostic value in very early dcSSc remains unclear.
Marzieh Jamali, Amisha Kaur, Suiyuan Huang, Carleigh Zahn, Erica Mulcaire‐Jones, John Varga, Dinesh Khanna   +6 more
wiley   +1 more source

Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth.

PLoS ONE, 2018
Bronchopulmonary dysplasia (BPD) remains the most common and serious chronic lung disease of premature infants. Severe BPD complicated with pulmonary hypertension (PH) increases the mortality of these infants. Riociguat is an allosteric soluble guanylate
Keyur Donda, Ronald Zambrano, Younghye Moon, Justin Percival, Ruben Vaidya, Fredrick Dapaah-Siakwan, Shihua Luo, Matthew R Duncan, Yong Bao, Luqing Wang, Ling Qin, Merline Benny, Karen Young, Shu Wu   +13 more
doaj   +1 more source

Riociguat reduces hyperoxia-induced PH.

, 2018
(A) Right ventricular systolic pressure (RVSP) was significantly increased in the hyperoxia + placebo treated group as compared with normoxia group. Riociguat administration significantly decreased RVSP during hyperoxia.
Ronald Zambrano (5497406), Younghye Moon (200726), Shu Wu (492135), Shihua Luo (5497415), Yong Bao (296790), Luqing Wang (5257895), Merline Benny (5497403), Justin Percival (5497412), Ling Qin (68169), Fredrick Dapaah-Siakwan (5497409), Matthew R. Duncan (5497421), Keyur Donda (5497400), Karen Young (833929), Ruben Vaidya (5497418)   +13 more
core   +1 more source

Pharmacological activation of NO‐cGMP signalling attenuates metabolic dysfunction‐associated steatohepatitis

British Journal of Pharmacology, Volume 183, Issue 18, Page 5476-5495, September 2026.
Background and Purpose Metabolic dysfunction‐associated steatohepatitis (MASH) is linked to activation of hepatic stellate cells (HSCs) to α‐smooth muscle actin–positive myofibroblasts that produce collagen and proinflammatory cytokines. Quiescent HSCs express the NO‐cGMP signalling axis.
Krithika Rajeeth, Malte Roessing, Moritz Lehners, Lisa Dietz, Anja Schmitt, Stephan Hailfinger, Andreas Peter, Leticia Quintanilla‐Martinez, Irene Gonzalez‐Menendez, Ingmar Mederacke, German Ott, Peter Sandner, Matthias Schwab, Robert Feil, Susanne Feil   +14 more
wiley   +1 more source

Meta‐Analysis of Real‐World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension

The Journal of Clinical Hypertension
Riociguat is a drug that improves hemodynamic parameters and increases the exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Esra Pamukçu, Mehmet Onur Kaya
doaj   +1 more source